Prostate Cancer

During a Targeted Oncology Case Based Peer Perspectives event, Neeraj Agarwal, MD, discussed the case of a 57-year-old male patient with nonmetastatic castration resistant prostate cancer.

A novel tubulin inhibitor VERU-111 has demonstrated promising early antitumor activity and tolerability in men with metastatic castration-resistant prostate cancer who have failed prior androgen receptor therapy, according to the results of a phase 1b/2 study.

Split-dosing of BXCL701 at 0.6 mg per day is a supported dosing strategy for the agent in combination with pembrolizumab as treatment of patients with metastatic castration-resistant prostate cancer, according to phase 1b/2 study results.

In a phase 2 trial, onvansertib, a polo-like kinase 1 inhibitor, combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer who have early abiraterone resistance, demonstrated a decent safety profile across 3 dosing schedules and efficacy in the evaluable arms.

CART-PSMA-TGFβRd as adoptive chimeric antigen receptor T-cell therapy administered as treatment of patients with metastatic castration-resistant prostate cancer appears safe and feasible.

A significant reduction in the risk of death was observed with the addition of sipuleucel-T to either abiraterone acetate or enzalutamide as treatment of patients with metastatic castration-resistant prostate cancer in a real-world analysis.

Neal D. Shore, MD, FACS, discusses the results of the retrospective review on real-world patterns of genomic testing in patients with metastatic castration-resistant prostate cancer.

Relugolix demonstrated a similar rate of castration resistance-free survival compared with the current standard of care leuprolide acetate as treatment of patients with metastatic prostate cancer.

Alicia K. Morgans, MD, MPH, discussed the case of a 75-year-old male with metastatic castration-resistant prostate cancer.

AMG 160 showed preliminary evidence of efficacy with a manageable safety profile as treatment of patients with metastatic castration-resistant prostate cancer who have been heavily pretreated.

A primary analysis from the phase 3 IPATential150 trial demonstrated the benefit of the addition of ipatasertib to abiraterone acetate and prednisone in the treatment of patients with metastatic castration-resistant prostate cancer with PTEN loss, according to results presented at the 2020 ESMO Virtual Congress.

Updated findings from the randomized, open-label phase 3 PROfound trial indicate that olaparib induces a significantly longer duration of overall survival versus enzalutamide or abiraterone plus prednisone in metastatic castration-resistant prostate cancer tumors with at least 1 alteration in BRCA1, BRCA2, or ATM and disease that has progressed during previous treatment with a next-generation hormonal agent.

PARP inhibitors have propelled the field of metastatic castration-resistant prostate cancer forward as the next class of therapeutics to advance outcomes.

A Fast Track designation has been granted by the FDA to EPI-7386, a selective androgen receptor inhibitor, which is a potential treatment for adult patients with metastatic castration-resistant prostate cancer that is resistant to standard-of-care therapy.

A higher percentage of patients with nonmetastatic castration-resistant prostate cancer were alive at 3 years on treatment with darolutamide compare with placebo, according to published results from the final analysis of the phase 3 ARAMIS clinical trial.

Michael J. Morris, MD, discusses the safety and clinical activity of atezolizumab plus radium-223 dichloride in patients with second-line metastatic castration-resistant prostate cancer.

In an interview with Targeted Oncology, Andrei Gafita, MD, discussed the recent findings from the international multicenter retrospective analysis of LuPSMA as treatment of patients with metastatic castration-resistant prostate cancer, and how these findings and more clinical trials could lead to the approval of this treatment for patients who have exhausted all other standard treatments.

During a virtual Case Base Peer Perspectives event, Eleni Efstathiou, MD, PhD, a discussed treatment options for a 57-year-old African American man with nonmetastaic castration resistant prostate cancer.

During a virtual Case Based Peer Perspectives event, David I. Quinn, MD, MBBS, PhD, reviewed the case of a 60-year old male patient with metastatic castration-resistant prostate cancer.

During a virtual Case Based Peer Perspectives event, Nicholas J. Vogelzang, MD, reviewed the case of a 75-year-old man diagnosed with metastatic castration-resistant prostate cancer.

Short and longterm safety and a meaningful reduction in worst pain were reported in patients with metastatic castration-resistant prostate cancer, based on results from the REASSURE trial.

The FDA placed a partial clinical hold on enrollment to the phase 1 P-PSMA-101-001 trial evaluating P-PSMA-01 as treatment of patients with metastatic castration-resistant prostate cancer.

Much of the most important work that must be done during the development of a new cancer medication is often accomplished long after FDA approval, wrote Arjun V. Balar, MD.

Andrei Gafita, MD, discusses the overall survival in patients with metastatic castration-resistant prostate cancer who received 177Lutetium-prostate-specific membrane antigen radionuclide treatment.

Prostate-specific antigen changes were observed 6 weeks after the administration of 177Lu-PSMA in men with metastatic castration-resistant prostate cancer, suggesting a prognostic value for long-term clinical benefit, according to a single center retrospective analysis.